The litigation targets the company’s conduct regarding its high-profile NHS-Galleri cancer screening trial. According to the complaint, GRAIL executives allegedly misled shareholders by promising a three-year follow-up period sufficient to prove a reduction in late-stage cancer diagnoses, while concealing internal data suggesting the study design was fundamentally flawed. These claims reached a breaking point on February 19, 2026, when the company admitted the trial failed to meet its primary endpoint and conceded that the follow-up timeline was likely inadequate.
Investors File Securities Fraud Class Action Against GRAIL
A securities fraud class action lawsuit has been launched against GRAIL, Inc. following a massive share price collapse that erased over $2.2 billion in market value. The firm Hagens Berman Sobol Shapiro LLP is now calling on investors who suffered losses between May 2025 and February 2026 to come forward.
The market reaction was immediate and severe. Shares of GRAL plummeted 50.55% in a single session, falling from $101.53 to $50.21. Reed Kathrein, the partner leading the investigation, stated the firm is specifically examining when management realized the trial’s duration was insufficient compared to what was publicly touted to investors. Those who held stock during the class period have until August 4, 2026, to apply for lead plaintiff status. Hagens Berman is also inviting whistleblowers with non-public information to assist in the ongoing probe, citing potential rewards under SEC programs for original disclosures.
Comments (0)
No comments yet. Be the first!